Dr.Nod: computational framework for discovery of regulatory non-coding drivers in tissue-matched distal regulatory elements

Abstract The discovery of cancer driver mutations is a fundamental goal in cancer research. While many cancer driver mutations have been discovered in the protein-coding genome, research into potential cancer drivers in the non-coding regions showed limited success so far. Here, we present a novel comprehensive framework Dr.Nod for detection of non-coding cis-regulatory candidate driver mutations that are associated with dysregulated gene expression using tissue-matched enhancer-gene annotations. Applying the framework to data from over 1500 tumours across eight tissues revealed a 4.4-fold enrichment of candidate driver mutations in regulatory regions of known cancer driver genes. An overarching conclusion that emerges is that the non-coding driver mutations contribute to cancer by significantly altering transcription factor binding sites, leading to upregulation of tissue-matched oncogenes and down-regulation of tumour-suppressor genes. Interestingly, more than half of the detected cancer-promoting non-coding regulatory driver mutations are over 20 kb distant from the cancer-associated genes they regulate. Our results show the importance of tissue-matched enhancer-gene maps, functional impact of mutations, and complex background mutagenesis model for the prediction of non-coding regulatory drivers. In conclusion, our study demonstrates that non-coding mutations in enhancers play a previously underappreciated role in cancer and dysregulation of clinically relevant target genes.

[1]  P. Campbell,et al.  Diverse mutational landscapes in human lymphocytes , 2022, Nature.

[2]  Ryan D. Morin,et al.  Super-enhancer hypermutation alters oncogene expression in B cell lymphoma , 2022, Nature.

[3]  Po-Ru Loh,et al.  Genome-wide mapping of somatic mutation rates uncovers drivers of cancer , 2022, Nature Biotechnology.

[4]  Sarah E. Williams,et al.  Mapping cis-regulatory elements in human neurons links psychiatric disease heritability and activity-regulated transcriptional programs , 2022, Cell reports.

[5]  Yanxia Yang,et al.  Cyclin D1 mediated by the nuclear translocation of nuclear factor kappa B exerts an oncogenic role in lung cancer , 2022, Bioengineered.

[6]  Lin Zhang,et al.  Systematic illumination of druggable genes in cancer genomes , 2022, Cell reports.

[7]  R. Bhandari,et al.  LINC01023 Promotes the Hepatoblastoma Tumorigenesis via miR-378a-5p/WNT3 Axis , 2022, Molecular and Cellular Biochemistry.

[8]  M. Hung,et al.  Endothelial p130cas confers resistance to anti-angiogenesis therapy , 2020, Cell reports.

[9]  E. Larsson,et al.  Non-coding driver mutations in human cancer , 2021, Nature Reviews Cancer.

[10]  Ryan L. Collins,et al.  Genome-wide enhancer maps link risk variants to disease genes , 2021, Nature.

[11]  L. Xue,et al.  Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors , 2021, Clinical epigenetics.

[12]  Qingfeng Sun,et al.  STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib , 2021, Journal of Hematology & Oncology.

[13]  Andrei Barbu,et al.  Multi-resolution modeling of a discrete stochastic process identifies causes of cancer , 2021, ICLR.

[14]  Xiyong Yu,et al.  CKS1B as Drug Resistance-Inducing Gene—A Potential Target to Improve Cancer Therapy , 2020, Frontiers in Oncology.

[15]  A. Gonzalez-Perez,et al.  A compendium of mutational cancer driver genes , 2020, Nature Reviews Cancer.

[16]  Erin L. Schenk,et al.  Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing , 2020, Cell.

[17]  Hengrui Zhu,et al.  PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications , 2020, Molecular Cancer.

[18]  Nuno A. Fonseca,et al.  Combined burden and functional impact tests for cancer driver discovery using DriverPower , 2020, Nature Communications.

[19]  Jun Yu,et al.  Analyses of non-coding somatic drivers in 2,658 cancer whole genomes , 2020, Nature.

[20]  Mathieu Lupien,et al.  Candidate Cancer Driver Mutations in Distal Regulatory Elements and Long-Range Chromatin Interaction Networks. , 2020, Molecular cell.

[21]  Icgc,et al.  Pan-cancer analysis of whole genomes , 2017, bioRxiv.

[22]  Neva C. Durand,et al.  Activity-by-Contact model of enhancer-promoter regulation from thousands of CRISPR perturbations , 2019, Nature Genetics.

[23]  W. Gong,et al.  Knockdown of linc01023 restrains glioma proliferation, migration and invasion by regulating IGF-1R/AKT pathway , 2019, Journal of Cancer.

[24]  A. Gonzalez-Perez,et al.  Local Determinants of the Mutational Landscape of the Human Genome , 2019, Cell.

[25]  H. Jacobs,et al.  Mutating for Good: DNA Damage Responses During Somatic Hypermutation , 2019, Front. Immunol..

[26]  Ville Mustonen,et al.  The repertoire of mutational signatures in human cancer , 2018, Nature.

[27]  Wenyu Zhu,et al.  Silence of Stomatin-Like Protein 2 Represses Migration and Invasion Ability of Human Liver Cancer Cells via Inhibiting the Nuclear Factor Kappa B (NF-κB) Pathway , 2018, Medical science monitor : international medical journal of experimental and clinical research.

[28]  C. Cole,et al.  The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers , 2018, Nature Reviews Cancer.

[29]  Cameron S. Osborne,et al.  Promoter capture Hi-C-based identification of recurrent noncoding mutations in colorectal cancer , 2018, Nature Genetics.

[30]  B. Schuster-Böckler,et al.  Mutational signature distribution varies with DNA replication timing and strand asymmetry , 2018, Genome Biology.

[31]  M. Tomková,et al.  DNA Modifications: Naturally More Error Prone? , 2018, Trends in genetics : TIG.

[32]  M. Stratton,et al.  Universal Patterns of Selection in Cancer and Somatic Tissues , 2018, Cell.

[33]  S. Rabbani,et al.  Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications , 2018, Front. Oncol..

[34]  M. Tomková,et al.  DNA Replication and associated repair pathways are involved in the mutagenesis of methylated cytosine. , 2018, DNA repair.

[35]  J. Bai,et al.  EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis , 2018, Journal of experimental & clinical cancer research : CR.

[36]  A. Page,et al.  Context-Dependent Role of IKKβ in Cancer , 2017, Genes.

[37]  Phillip G. Montgomery,et al.  Defining a Cancer Dependency Map , 2017, Cell.

[38]  F. Supek,et al.  Clustered Mutation Signatures Reveal that Error-Prone DNA Repair Targets Mutations to Active Genes , 2017, Cell.

[39]  Doron Lancet,et al.  MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search , 2016, Nucleic Acids Res..

[40]  Ferran Reverter,et al.  Discovery of Cancer Driver Long Noncoding RNAs across 1112 Tumour Genomes: New Candidates and Distinguishing Features , 2016, Scientific Reports.

[41]  Nicholas A. Sinnott-Armstrong,et al.  Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer , 2016, Nature Genetics.

[42]  M. Tomková,et al.  5-hydroxymethylcytosine marks regions with reduced mutation frequency in human DNA , 2016, eLife.

[43]  J. Chaudhuri,et al.  Mutations, kataegis and translocations in B cells: understanding AID promiscuous activity , 2016, Nature Reviews Immunology.

[44]  P. Hanawalt,et al.  Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair , 2016, Cell.

[45]  A. Valencia,et al.  Non-coding recurrent mutations in chronic lymphocytic leukaemia , 2015, Nature.

[46]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[47]  Paz Polak,et al.  Cell-of-origin chromatin organization shapes the mutational landscape of cancer , 2015, Nature.

[48]  R. Young,et al.  An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element , 2014, Science.

[49]  Kevin Y. Yip,et al.  FunSeq2: a framework for prioritizing noncoding regulatory variants in cancer , 2014, Genome Biology.

[50]  W. Hahn,et al.  PRKACA Mediates Resistance to HER2-Targeted Therapy in Breast Cancer Cells and Restores Anti-Apoptotic Signaling , 2014, Oncogene.

[51]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[52]  J. Stamatoyannopoulos,et al.  Reduced local mutation density in regulatory DNA of cancer genomes is linked to DNA repair , 2013, Nature Biotechnology.

[53]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[54]  D. Leprince,et al.  Deciphering HIC1 control pathways to reveal new avenues in cancer therapeutics , 2013, Expert opinion on therapeutic targets.

[55]  D. Schadendorf,et al.  TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.

[56]  M. Stratton,et al.  Deciphering Signatures of Mutational Processes Operative in Human Cancer , 2013, Cell reports.

[57]  Chun-Ming Wong,et al.  Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis , 2012, Hepatology.

[58]  B. Schuster-Böckler,et al.  Chromatin organization is a major influence on regional mutation rates in human cancer cells , 2012, Nature.

[59]  W. Hall,et al.  Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer , 2012, Journal of Neuro-Oncology.

[60]  Mei X. Wu,et al.  IEX-1 Deficiency Protects against Colonic Cancer , 2012, Molecular Cancer Research.

[61]  Prahlad T. Ram,et al.  Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. , 2011, Journal of the National Cancer Institute.

[62]  D. Leprince,et al.  Differential Regulation of HIC1 Target Genes by CtBP and NuRD, via an Acetylation/SUMOylation Switch, in Quiescent versus Proliferating Cells , 2010, Molecular and Cellular Biology.

[63]  Aaron R. Quinlan,et al.  BIOINFORMATICS APPLICATIONS NOTE , 2022 .

[64]  Rachael P. Huntley,et al.  QuickGO: a web-based tool for Gene Ontology searching , 2009, Bioinform..

[65]  Morton B. Brown 400: A Method for Combining Non-Independent, One-Sided Tests of Significance , 1975 .

[66]  D. Schadendorf,et al.  Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2022 .